Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III GOYA study evaluating Gazyva® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in ... Biopharmaceuticals, OncologyGenentech, Gazyva, obinutuzumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news